THE European Union has
approved marketing authorisation
for Shire plc’s new a human cell
line derived enzyme replacement
therapy treatment VPRIV(R)
(velaglucerase alfa).
Indicated for treatment of type 1
Gaucher disease VPRIV(R) will
soon be available in 30 European
countries.
“Gaucher disease is a rare and
often debilitating condition,” said
Professor Tim Cox from the
Department of Medicine,
University of Cambridge.
“The European approval of
VPRIV is important in that we now
have an alternative, licensed
therapeutic enzyme.
“For type 1 patients the
availability of VPRIV provides
further opportunities to
individualise treatment options for
this complex disorder,” Cox added.The above article was sent to subscribers in Pharmacy Daily's issue from 27 Aug 10 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 27 Aug 10
IN WESTERN Australia, Michael’s Chemist Group has started stocking therapeutic Nicotine Vaping Products (NVPs), pursuant to the Federal Government’s new vaping laws (PD 25 Mar).
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.